Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2013

Conditions
Iron-Deficiency Anemia
Interventions
DRUG

Ferric carboxymaltose

"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."

Trial Locations (2)

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

SE-112 81

Department of Medicine, St Görans Hospital (Capio St Görans Sjukhus), Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Vifor Pharma

INDUSTRY